ArticleFrontiers in pharmacology2026

Tislelizumab combined with Anti-GD2 antibody-based chemoimmunotherapy for pediatric relapsed/refractory high-risk neuroblastoma: a two-Case Report.

Ting Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.